Restored credibility for sepsis therapeutics?
Article Abstract:
XOMA Corporation has nearly finished with the phase III clinical trials of Neuprex, a treatment for meningococcal sepsis. Currently, no approved therapeutic treatment exists for the afflicition, a systemic inflammatory response syndrom that has a mortality rate in excess of 25%. The search for a treatment for sepsis was meet with several clinical failures, leaving clinicians to conclude that the biology of the malady was too poorly understood to devise an effective treatment. Neuprex differs from past sepsis treatment in that it is a potent neutralizer of endotoxin, a mediaotor of the sepsis cascade. Such previous drugs as Centozin were unable to stop the binding of another mediator in the sepsis cascade, lipopolysachharide-binding protein (LBP).
Comment:
XOMA Corporation has nearly finished with the phase III clinical trials of Neuprex, a treatment for meningococcal sepsis.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
Rapid-response vaccines: Does DNA offer a solution?
Article Abstract:
The world is in an unsteady position on the verge of a massive influenza outbreak as the existing manufacturers are unlikely to have sufficient production capacity to produce new vaccines at the scale and speed required to protect public health. It is argued that countries with established vaccine production infrastructure must invest greater effort and resources into developing innovative DNA vaccine technology, which ultimately might empower more countries to produce their own vaccines.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
User Contributions:
Comment about this article or add new information about this topic:
Do targets limit antibiotic discovery?
Article Abstract:
Drug discovery requires optimism and compromise at every stage as targets and compounds are not perfect, and sometimes the positive effects of compounds are confounded by their side effects. The real challenge lies in finding safe and effective compounds for antibiotics and the resulting antibiotics must also compete effectively against the numerous antibiotics already existing in the market.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Human push capability. Good vibrations: Do electrical therapeutic massagers work? Effects of an electric blanket on sleep stages and body temperature in young men
- Abstracts: Alfred E. Mann. A real case of not getting older, getting better
- Abstracts: Calreticulin exposure increases cancer immunogenicity. Immunotherapy for pancreatic cancer: Science driving clinical progress
- Abstracts: Task and training requirements analysis methodology (TTRAM): an analytic methodology for identifying potential training uses of simulator networks in teamwork-intensive task environments
- Abstracts: Managing your compensation expectations in today's environment: a second look